- $2.68m
- $10.06m
- $24.22m
- 48
- 88
- 14
- 49
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.3 | ||
| Price to Tang. Book | 0.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -18.93% | ||
| Return on Equity | -30.95% | ||
| Operating Margin | -10.36% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 32.34 | 35.97 | 23.18 | 23.07 | 24.21 | n/a | n/a | -5.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -85.4 | +3619.2 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cyanotech Corporation is engaged in sustainable microalgae cultivation, producing high-value natural ingredients and dietary supplement products for health and wellness. The Company, through its microalgae technology, produces BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. Its BioAstin Hawaiian Astaxanthin offers antioxidant activity which supports skin, eye and joint health, as well as recovery from exercise. Hawaiian Spirulina Pacifica is a nutrient-rich superfood dietary supplement clinically supported for natural energy, immune system support, cardiovascular health and as a concentrated source of protein, antioxidant carotenoids, and essential nutrients. Its products are produced from microalgae grown at its 96-acre facility in Kona, Hawaii. It sells its products direct to consumers at retail locations in the United States and online at www.nutrex-hawaii.com and also distributes to dietary supplement, nutraceutical and cosmeceutical manufacturers and marketers.
Directors
- Michael Davis NEC (68)
- Matthew Custer PRE (38)
- Gerald Cysewski CEO (72)
- Felicia Ladin CFO (49)
- Glenn Jensen VOP (63)
- Amy Nordin VPR (53)
- Jennifer Johansen VPR (48)
- Nancy Katz IND (62)
- Angela Mc Elwee IND
- Walter Menzel IND (74)
- David Mulder IND (60)
- David Vied IND (60)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- March 3rd, 1980
- Public Since
- May 21st, 1999
- No. of Shareholders
- 472
- No. of Employees
- 83
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq- Shares in Issue
- 7,232,217
- Address
- 73-4460 Queen Kaahumanu Hwy, Suite #102, KAILUA KONA, 96740
- Web
- https://www.cyanotech.com/
- Phone
- +1 8083261353
- Contact
- Jennifer Rogerson
- Auditors
- BPM LLP
Upcoming Events for CYAN
Cyanotech Corp Annual Shareholders Meeting
Q2 2026 Cyanotech Corp Earnings Release
Similar to CYAN
Acusphere
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
Aleafia Health
Pink Sheets on Nasdaq
FAQ
What is the Cyanotech share price?
As of Today at 20:08 UTC, shares in Cyanotech are trading at $0.37. This share price information is delayed by 15 minutes.
How has the Cyanotech share price performed this year?
Shares in Cyanotech last closed at $0.37 and the price had moved by -47.14% over the past 365 days. In terms of relative price strength the Cyanotech share price has underperformed the S&P500 Index by -54.99% over the past year.
What are the analyst and broker recommendations for Cyanotech?
There is no consensus recommendation for this security.
Find out moreWhat is the Cyanotech dividend yield?
Cyanotech does not currently pay a dividend.
Does Cyanotech pay a dividend?
Cyanotech does not currently pay a dividend.
When does Cyanotech next pay dividends?
Cyanotech does not currently pay a dividend.
How do I buy Cyanotech shares?
To buy shares in Cyanotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cyanotech?
As of the previous close price of $0.37, shares in Cyanotech had a market capitalisation of $2.68m.
Where are Cyanotech shares listed?
Here are the trading details for Cyanotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CYAN
What kind of share is Cyanotech?
Based on an overall assessment of its quality, value and momentum Cyanotech is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cyanotech share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cyanotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cyanotech. Over the past six months, its share price has underperformed the S&P500 Index by -0.16%.
As of the last closing price of $0.37, shares in Cyanotech were trading -19.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cyanotech PE Ratio?
The Cyanotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cyanotech?
Cyanotech's management team is headed by:
- Michael Davis - NEC
- Matthew Custer - PRE
- Gerald Cysewski - CEO
- Felicia Ladin - CFO
- Glenn Jensen - VOP
- Amy Nordin - VPR
- Jennifer Johansen - VPR
- Nancy Katz - IND
- Angela Mc Elwee - IND
- Walter Menzel - IND
- David Mulder - IND
- David Vied - IND